Moody Aldrich Partners LLC Intellia Therapeutics, Inc. Transaction History

Moody Aldrich Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	BUY	$53.92 - $71.7 $1.08 Million - $1.44 Million	20,119 New	20,119 $1.13 Million
Q2 2022 Jul 18, 2022	SELL	$38.49 - $76.21 $1.28 Million - $2.54 Million	-33,358 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$58.27 - $118.99 $215,599 - $440,263	3,700 Added 12.48%	33,358 $2.42 Million
Q4 2021 Feb 02, 2022	SELL	$100.76 - $138.36 $538,259 - $739,119	-5,342 Reduced 15.26%	29,658 $3.51 Million
Q3 2021 Oct 29, 2021	BUY	$132.37 - $176.78 $636,567 - $850,135	4,809 Added 15.93%	35,000 $4.7 Million
Q2 2021 Aug 04, 2021	BUY	$60.88 - $161.91 $1.84 Million - $4.89 Million	30,191 New	30,191 $4.89 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.